Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Infection and Immunity Theme, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
J Glob Health. 2022 Aug 22;12:10004. doi: 10.7189/jogh.12.10004.
Streptococcus pneumoniae is one of the most common bacteria causing pneumonia and the World Health Organization (WHO) recommends first-line treatment of pneumonia with penicillins. Due to increases in the frequency of penicillin resistance, this systematic review aimed to determine the clinical outcomes of children with pneumonia in low- and middle-income countries (LMICs), with penicillin-group resistant pneumococci in respiratory and/or blood cultures specimens.
English-language articles from January 2000 to November 2020 were identified by searching four databases. Systematic reviews and epidemiological studies from LMICs that included children aged one month to 9 years and reported outcomes of pneumonia with a penicillin-resistant pneumococcus in respiratory and blood culture specimens with or without comparison groups were included. Risk of bias was assessed using the Effective Public Health Practice Project (EPHPP) Quality Assessment Tool for Quantitative Studies. A narrative synthesis of findings based on the results of included studies was performed.
We included 7 articles involving 2864 children. One strong- and four medium-quality studies showed no difference in clinical outcomes (duration of symptoms, length of hospital stay and mortality) between those children with penicillin non-susceptible compared to susceptible pneumococci. Two weak quality studies suggested better outcomes in the penicillin-susceptible group.
Current evidence suggests no difference in clinical outcomes of child pneumonia due to a penicillin-resistant S. pneumoniae and as such, there is no evidence to support a change in current WHO antibiotic guidelines.
肺炎链球菌是引起肺炎的最常见细菌之一,世界卫生组织(WHO)建议使用青霉素作为一线治疗肺炎的药物。由于青霉素耐药性的增加,本系统评价旨在确定中低收入国家(LMIC)中儿童肺炎的临床结局,这些儿童的呼吸道和/或血液培养标本中存在青霉素耐药肺炎链球菌。
通过搜索四个数据库,确定了 2000 年 1 月至 2020 年 11 月的英文文章。纳入了包括 1 个月至 9 岁儿童在内的来自 LMIC 的系统评价和流行病学研究,这些研究报告了呼吸道和血液培养标本中存在青霉素耐药肺炎链球菌的肺炎的结局,且有或没有对照组。使用有效公共卫生实践项目(EPHPP)质量评估工具对定量研究进行了偏倚风险评估。根据纳入研究的结果,对研究结果进行了叙述性综合。
我们纳入了 7 篇涉及 2864 名儿童的文章。1 项强质量和 4 项中等质量的研究表明,青霉素不敏感与敏感肺炎链球菌相比,儿童的临床结局(症状持续时间、住院时间和死亡率)没有差异。2 项弱质量研究表明青霉素敏感组的结局更好。
目前的证据表明,青霉素耐药性 S. pneumoniae 引起的儿童肺炎临床结局没有差异,因此,没有证据支持改变目前的世卫组织抗生素指南。